Advanced HR+/HER2- Breast Cancer research hub

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

This study looks at a new drug, ECI830, for advanced breast cancer and other solid tumors. Researchers want to see if it's safe and effective, both alone and with other common cancer medicines.